Estrella Immunopharma (ESLA) Stock Price, Quote, News & History

Comments

Estrella Immunopharma Inc (ESLA) Stock Price, Quote, News & History

ESLANASDAQ

Trade with Public

$1.35

0.097.14%

Last update: Mar 16, 5:39 AM

OverviewNews Earnings Analyst Ratings Short Interest Stock Report

Key Statistics

Open

$1.35

Close

-

Volume / Avg.

24.52K / 177.03K

Day Range

$1.22 - $1.35

52 Wk Range

0.73 - 3.15

Market Cap

$50.98M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

53

Short Interest

5.47%

Days to Cover

16.22

Recent Estrella Immunopharma Inc News

PRO
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $8 Price Target

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
Estrella Immunopharma Presents Updated EB103 Data Showing 100% Complete Response In High-Dose Cohort At 2026 ASTCT And CIBMTR Tandem Meetings

Benzinga Newsdesk

PRO
Estrella Immunopharma To Present Late-Breaking Phase 1 Data For EB103 in Aggressive B-Cell NHL At 2026 ASTCT & CIBMTR Tandem Meetings

Benzinga Newsdesk

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-18.01M

Investing Cash Flow (TTM)

5.07M

Financing Cash Flow (TTM)

-7.40M

Free Cash Flow (TTM)

-18.01M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-20.34M

Analyst Trends and Forecast

1

Nov 25

1

Jan

1

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$51.34M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-19.34%

Earnings Yield % (FWD)

-32.54%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.23

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

-

Total Cash

$1.63M

Debt to Equity

-

Issuance of Debt (TTM)

-$300.00K

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.35

Close

-

Volume / Avg.

24.52K / 177.03K

Day Range

$1.22 - $1.35

52 Wk Range

0.73 - 3.15

Market Cap

$50.98M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

53

Short Interest

5.47%

Days to Cover

16.22

About

Sector

Health Care

Industry

Biotechnology

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

Q

How do I buy Estrella Immunopharma (ESLA) stock?

A

You can purchase shares of Estrella Immunopharma (NASDAQ:ESLA) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Estrella Immunopharma (ESLA) competitors?

A

Other companies in Estrella Immunopharma’s space includes: Kezar Life Sciences Inc (NASDAQ:KZR), Atossa Therapeutics Inc (NASDAQ:ATOS), Aligos Therapeutics Inc (NASDAQ:ALGS), Entera Bio Ltd (NASDAQ:ENTX) and Forum Markets Inc (NASDAQ:FRMM).

Q

What is the forecast, or price target, for Estrella Immunopharma (ESLA) stock?

A

Estrella Immunopharma has a consensus price target of $8.00.

Q

What is the current price for Estrella Immunopharma (ESLA)?

A

The stock price for Estrella Immunopharma (NASDAQ: ESLA) is $1.35 last updated March 16, 2026 at 5:39 AM EDT.

Q

Does Estrella Immunopharma (ESLA) pay a dividend?

A

There are no upcoming dividends for Estrella Immunopharma.

Q

When is Estrella Immunopharma (NASDAQ:ESLA) reporting earnings?

A

Estrella Immunopharma does not have any upcoming earnings scheduled.

Q

Is Estrella Immunopharma (ESLA) going to split?

A

There is no upcoming split for Estrella Immunopharma.

Q

What sector and industry does Estrella Immunopharma (ESLA) operate in?

A

Estrella Immunopharma is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Kezar Life Sciences Inc

NASDAQ:KZR

$7.30

0.88%

Atossa Therapeutics Inc

NASDAQ:ATOS

$5.00

-0.20%

Aligos Therapeutics Inc

Lisata Therapeutics Inc

NASDAQ:LSTA

$5.02

-0.20%

Key Statistics

Open

$1.35

Close

-

Volume / Avg.

24.52K / 177.03K

Day Range

$1.22 - $1.35

52 Wk Range

0.73 - 3.15

Market Cap

$50.98M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

53

Short Interest

5.47%

Days to Cover

16.22

Recent Estrella Immunopharma Inc News

PRO
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $8 Price Target

D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $8 price target.

Benzinga Newsdesk

PRO
Estrella Immunopharma Presents Updated EB103 Data Showing 100% Complete Response In High-Dose Cohort At 2026 ASTCT And CIBMTR Tandem Meetings

Benzinga Newsdesk

PRO
Estrella Immunopharma To Present Late-Breaking Phase 1 Data For EB103 in Aggressive B-Cell NHL At 2026 ASTCT & CIBMTR Tandem Meetings

Benzinga Newsdesk

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

-18.01M

Investing Cash Flow (TTM)

5.07M

Financing Cash Flow (TTM)

-7.40M

Free Cash Flow (TTM)

-18.01M

Capital Expenditure (TTM)

-

Net Change in Cash (TTM)

-20.34M

Analyst Trends and Forecast

1

Nov 25

1

Jan

1

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$51.34M

PE Ratio (TTM)

-

PE Ratio (FWD)

-

PEG Ratio (TTM)

-

PS Ratio (TTM)

-

PB Ratio (TTM)

-

Earnings Yield % (TTM)

-19.34%

Earnings Yield % (FWD)

-32.54%

EV / EBITDA (TTM)

-

Price / EBITDA (TTM)

-

Price / Free Cash Flow (TTM)

-

Book Value / Share

-$0.23

Company Debt

Total Debt

-

LT Debt

-

LT Debt Issuance (TTM)

$0

LT Debt Repayment (TTM)

-

Total Cash

$1.63M

Debt to Equity

-

Issuance of Debt (TTM)

-$300.00K

Repayment of Debt (TTM)

-

Key Statistics

Open

$1.35

Close

-

Volume / Avg.

24.52K / 177.03K

Day Range

$1.22 - $1.35

52 Wk Range

0.73 - 3.15

Market Cap

$50.98M

P/E Ratio

-

Dividend Yield

-

Exchange

NASDAQ

RSI

53

Short Interest

5.47%

Days to Cover

16.22

About

Sector

Health Care

Industry

Biotechnology

Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission ...

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry